WEXFORD,
Pa., Sept. 19, 2024 /PRNewswire/ -- Coeptis
Therapeutics Holdings, Inc. (Nasdaq: COEP) (the "Company" or
"Coeptis"), a biopharmaceutical company developing innovative cell
therapy platforms for cancer, autoimmune, and infectious diseases,
announced today that it has received a notification letter from
the Nasdaq Hearings Panel (the "Panel") granting its
request for continued listing on The Nasdaq Stock Market ("Nasdaq")
through January 15, 2025, subject to
the Company demonstrating compliance with Nasdaq Listing Rule
5550(a)(2).
As previously disclosed, on January 29,
2024, the Company received a letter from the Listing
Qualifications Staff of Nasdaq indicating that, based upon the
closing bid price of the Company's common stock, for the last 30
consecutive business days, the Company was not in compliance with
the requirement to maintain a minimum bid price of $1.00 per share (the "Minimum Bid Price
Requirement") for continued listing as set forth in Nasdaq Listing
Rule 5550(a)(2) (the "Original Notice"). At that time, the Company
was provided a compliance period of 180 calendar days from the date
of the Original Notice, or until July 29,
2024, to regain compliance with the Minimum Bid Price
Requirement, pursuant to Nasdaq Listing Rule
5810(c)(3)(A).
On September 12th, Coeptis presented a plan
before the Panel to address the minimum bid price requirement,
including its intent to implement a reverse stock split. The Panel
issued its decision on September
17th with the extension granted.
"We are pleased with the decision from Nasdaq to grant us our
extension," said Dave Mehalick
President and Chief Executive Officer of Coeptis. "We look
forward to regaining and maintaining compliance with Nasdaq's
continued listing requirements and continuing to focus on our goal
of improving patient outcomes."
About Coeptis Therapeutics Holdings, Inc.
Coeptis
Therapeutics Holdings, Inc., together with its subsidiaries
including Coeptis Therapeutics, Inc. and Coeptis Pharmaceuticals,
Inc., (collectively "Coeptis"), is a biopharmaceutical company
developing innovative cell therapy platforms for cancer,
autoimmune, and infectious diseases that have the potential to
disrupt conventional treatment paradigms and improve patient
outcomes. Coeptis' product portfolio and rights are highlighted by
assets licensed from Deverra Therapeutics, including an allogeneic
cellular immunotherapy platform and DVX201, a clinical-stage,
unmodified natural killer cell therapy technology. Additionally,
Coeptis is developing a universal, multi-antigen CAR T technology
licensed from the University of
Pittsburgh (SNAP-CAR), and the GEAR cell therapy and
companion diagnostic platforms, which Coeptis is developing with
VyGen-Bio and leading medical researchers at the Karolinska Institutet. Coeptis' business model is
designed around maximizing the value of its current product
portfolio and rights through in-license agreements, out-license
agreements and co-development relationships, as well as entering
into strategic partnerships to expand its product rights and
offerings, specifically those targeting cancer and infectious
diseases. The Company is headquartered in Wexford, PA. For more information on Coeptis
visit https://coeptistx.com/.
Cautionary Note Regarding Forward-Looking
Statements
This press release and statements of our
management made in connection therewith contain or may contain
"forward-looking statements" (as defined in Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended). Forward-looking
statements include statements concerning our plans, objectives,
goals, strategies, future events or performance, and underlying
assumptions, and other statements that are other than statements of
historical facts. When we use words such as "may," "will,"
"intend," "should," "believe," "expect," "anticipate," "project,"
"estimate" or similar expressions that do not relate solely to
historical matters, we are making forward-looking statements.
Forward-looking statements are not a guarantee of future
performance and involve significant risks and uncertainties that
may cause the actual results to differ materially and perhaps
substantially from our expectations discussed in the
forward-looking statements. Factors that may cause such differences
include but are not limited to: (1) the inability to maintain the
listing of the Company's securities on the Nasdaq Capital Market;
(2) the inability to recognize the anticipated benefits of the
Deverra licensed assets, which may be affected by, among other
things, competition, the ability of the Company to grow and manage
growth economically and hire and retain key employees; (3) the
risks that the Company's products in development or the
newly-licensed assets fail clinical trials or are not approved by
the U.S. Food and Drug Administration or other applicable
regulatory authorities; (4) costs related to ongoing asset
development including the Deverra licensed assets and pursuing the
contemplated asset development paths; (5) changes in applicable
laws or regulations; (6) the possibility that the Company may be
adversely affected by other economic, business, and/or competitive
factors; and (7) the impact of the global COVID-19 pandemic on any
of the foregoing risks and other risks and uncertainties identified
in the Company's filings with the Securities and Exchange
Commission (the "SEC"). The foregoing list of factors is not
exclusive. All forward-looking statements are subject to
significant uncertainties and risks including, but not limited, to
those risks contained or to be contained in reports and other
filings filed by the Company with the SEC. For these reasons, among
others, investors are cautioned not to place undue reliance upon
any forward-looking statements in this press release. Additional
factors are discussed in the Company's filings made or to be made
with the SEC, which are available for review at www.sec.gov. We
undertake no obligation to publicly revise these forward-looking
statements to reflect events or circumstances that arise after the
date hereof unless required by applicable laws, regulations, or
rules.
Contacts
Coeptis Therapeutics, Inc.
IR@coeptistx.com
800-478-8070
View original content to download
multimedia:https://www.prnewswire.com/news-releases/coeptis-therapeutics-regains-compliance-with-nasdaq-minimum-bid-price-requirement-for-continued-listing-302252568.html
SOURCE Coeptis Therapeutics, Inc.
